Masked priming with graphemically related forms: Repetition or partial activation?

Form-priming occurs when a prime that is graphemically similar to the target word facilitates processing of the target. In an activation model (such as Morton's logogen model), such an effect can be interpreted as a partial-activation effect. A prime that shares letters with the target must inevitably produce activation in the detectors for both the prime and the target. Alternatively, form-priming could be seen as a special case of repetition-priming, in which the prime actually accesses the entry for the target. It is shown that masked-priming effects in the lexical decision task can be obtained for graphemically related pairs such as bontrast-CONTRAST, but not for four-letter pairs such as bamp-CAMP. It is suggested that the priming effect is controlled by neighbourhood density, short words usually having many neighbours, long words having very few. This hypothesis is supported by the finding that form-priming does occur for four-letter words if the prime and target are drawn from low-density neighbourhoods. For a partial-activation theory, an inhibitory mechanism that is sensitive to the number of prime-neighbours is required to explain the results. Of the several versions of a repetition account considered, the “best match” hypothesis appears to be the most promising: this assumes that priming is limited to the stimulus that best matches the prime. It is also shown that prime-target pairs that are related in form and meaning (e.g. made-MAKE) produce the same priming effect as identical pairs, as predicted by a repetition account that assumes a common entry underlying both forms.

Mineral analysis of complete dog and cat foods in the UK and compliance with European guidelines

Mineral content of complete pet food is regulated to ensure health of the companion animal population. Analysis of adherence to these regulatory guidelines has not been conducted. Here, mineral composition of complete wet (n = 97) and dry (n = 80) canine and feline pet food sold in the UK was measured to assess compliance with EU guidelines. A majority of foods complied with ≥8 of 11 guidelines (99% and 83% for dry and wet food, respectively), but many failed to provide nutritional minimum (e.g. Cu, 20% of wet food) or exceeded nutritional maximum (e.g. Se, 76% of wet food). Only 6% (6/97) of wet and 38% (30/80) of dry food were fully compliant. Some foods (20–30% of all analysed) had mineral imbalance, such as not having the recommended ratio of Ca:P (between 1:1 to 2:1). Foods with high fish content had high levels of undesirable metal elements such as arsenic. This study highlights broad non-compliance of a range of popular pet foods sold in the UK with EU guidelines (94% and 61% of wet and dry foods, respectively). If fed exclusively and over an extended period, a number of these pet foods could impact the general health of companion animals.

A Comparison of Compliance and Noncompliance in Breast Cancer Screening among African American Women

African American women are more likely to be diagnosed with late stage breast cancer, due in part to low participation in screening procedures. The purpose of this study was to explore the differences among African American women who were compliant and noncompliant with standard mammography screening recommendations. The study participants were African American women (N = 599) over the age of 40 with no history of cancer, who were recruited to attend a local community health event. Findings revealed that 78 percent of the women reported having had a mammogram within the past year, whereas 22 percent had not. The most commonly reported reasons given by those who did not have a mammogram in the past year were that they simply did not think to do so, or that they were not told to do so by their doctor. Women who reported that they did not have a mammogram last year were significantly less likely to have health insurance, to have had a clinical breast exam at their last checkup, to have had their breasts examined by their doctor at least once per year, or to have previously had a mammogram. There were no group differences in the number of visits to a doctor during the past 12 months. The article concludes with a discussion of the implications for health care professionals and suggestions for future research.

Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund

BACKGROUND

The NHS Cancer Drugs Fund (CDF) was established in 2010 to reduce delays and improve access to cancer drugs, including those that had been previously appraised but not approved by NICE (National Institute for Health and Care Excellence). After 1.3 billion GBP expenditure, a UK parliamentary review in 2016 rationalized the CDF back into NICE.

METHODS

This paper analyses the potential value delivered by the CDF according to six value criteria. This includes validated clinical benefits scales, cost-effectiveness criteria as defined by NICE and an assessment of real-world data. The analysis focuses on 29 cancer drugs approved for 47 indications that could be prescribed through the CDF in January 2015.

RESULTS

Of the 47 CDF approved indications, only 18 (38%) reported a statistically significant OS benefit, with an overall median survival of 3.1 months (1.4-15.7 months). When assessed according to clinical benefit scales, only 23 (48%) and 9 (18%) of the 47 drug indications met ASCO and ESMO criteria, respectively. NICE had previously rejected 26 (55%) of the CDF approved indications because they did not meet cost-effectiveness thresholds. Four drugs-bevacizumab, cetuximab, everolimus and lapatinib-represented the bulk of CDF applications and were approved for a total of 18 separate indications. Thirteen of these indications were subsequently delisted by the CDF in January 2015 due to insufficient evidence for clinical benefit-data which were unchanged since their initial approval.

CONCLUSIONS

We conclude the CDF has not delivered meaningful value to patients or society. There is no empirical evidence to support a 'drug only' ring fenced cancer fund relative to concomitant investments in other cancer domains such as surgery and radiotherapy, or other noncancer medicines. Reimbursement decisions for all drugs and interventions within cancer care should be made through appropriate health technology appraisal processes.

Experiences of partners of prostate cancer survivors: A qualitative study

Prostate cancer, Australia's leading cancer, has treatment side effects that reduce the quality of life for both survivors and partners. Limited partner research exists. This study aimed to address this gap in the literature by gathering data directly from partners to obtain a deeper understanding of their experiences of prostate cancer survivorship that helps inform healthcare service providers. A qualitative approach was taken to explore participant views (N = 16) through three focus groups and two in-depth interviews. Five themes emerged relating to caregiver burden, knowledge deficit, isolation, changes of sexual relations, and unmet needs. Possible implications for practice may include the need for specific partner-related information and interventions to assist couples to cope with the emotional distress caused by treatment side effects.

Association Between Duration of Human Immunodeficiency Virus (HIV)-1 Viral Suppression Prior to Renal Transplantation and Acute Cellular Rejection

Renal transplant has become an important option for human immunodeficiency virus (HIV)-infected patients with end-stage renal disease; however, these patients experience a high rate of acute cellular rejection (ACR). Guidelines do not currently exist for the optimal duration of viral suppression prior to transplantation. In a retrospective cohort analysis of 47 HIV-infected renal transplant recipients, we compared the rate of ACR between patients based on the length of time of viral suppression prior to transplantation. Of the patients who achieved viral suppression for >6 months but less than 2 years prior to transplantation (n = 15), 60% experienced ACR compared to 41% of patients suppressed at least 2 years or more (n = 32) prior to transplant (p = 0.21). Patients suppressed <2 years experienced ACR at 2.48 times the rate of those suppressed 2 years or longer. Induction immunosuppression, HLA mismatch and panel-reactive antibodies (PRAs) did not significantly differ between the two groups.

A Holistic Model of Care to Support Those Living with and beyond Cancer

BACKGROUND

Globally, the burden of cancer continues to increase and it is well-documented that while not a homogeneous population, cancer patients and cancer survivors face many physical, psychological, social, spiritual, and financial issues. Cancer care is shifting from a disease-focused to a patient-centered approach resulting in an increased need to address these concerns.

METHODS

Utilizing a quality improvement approach, this paper describes an integrated cancer care model at Bloomhill Cancer Center (BCC) in Queensland, Australia that demonstrates the ability to meet the holistic needs of patients living with and beyond cancer and to identify opportunities for better practice and service provision.

RESULTS

Survey results indicate that 67% and 77% of respondents were very satisfied and 27% and 17% were satisfied with their first contact and very satisfied with their first meeting with a nurse at BCC. Clients also reported being very satisfied (46%) or satisfied (30%) with the emotional support they received at BCC and over 90% were very satisfied or satisfied with the touch therapies that the received.

CONCLUSION

Due to the early success of the interventions provided by BCC, the model potentially offers other states and countries a framework for supportive cancer care provision for people living with and beyond cancer.